Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Larotinib - Sunshine Lake Pharma

Next Previous
Drug Profile

Larotinib - Sunshine Lake Pharma

Alternative Names: 14C - larotinib; Z 650

Latest Information Update: 06 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HEC Pharm
  • Developer HEC Pharm; Sunshine Lake Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Oesophageal cancer
  • No development reported Pancreatic cancer
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 06 Feb 2026 Larotinib is still in phase-III clinical trials in Oesophageal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in China (PO) (NCT04415853)
  • 28 Sep 2023 Sunshine Lake Pharma completes a phase I Drug-drug interaction trial (In volunteers) in China (PO) (NCT05057949)
  • 28 Dec 2022 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Metastatic disease, Recurrent) in China (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top